Alembic Pharmaceuticals received an FDA warning letter for failing to label a bioequivalence study as
July 21, 2026 01:22 PM EDT
Indian generic drugmaker gets FDA warning over clinical study consent
Indian generic drugmaker Alembic Pharmaceuticals has been hit with an FDA warning letter after failing to get informed consent from patients for a clinical study.
…
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Following an inspection earlier this year that yielded a Form 483, Indian generics juggernaut Alembic Pharmaceuticals has…
The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading…
The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has…
After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the Sanofi subsidiary is facing…
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufacturing sites with…
